Shankar Venkatraman Email & Phone Number | Proven drug discovery leader with over twenty years of drug discovery experience and successful track record in managing programs with 8 IND filings and one drug (Revumenib). Managed programs starting from target validation to identification of hits via SBDD/FBDD/HTS/DEL/literature and utilized PROTAC’s, molecular glues, covalent inhibitors, and allosteric modulators a to identify development and clinical candidates. Extensive experience in peptide therapeutics (Enkephalin analogs, VLA4 antagonist, PCSK9). Broad experience in various disease pathology including Alzheimer’s, Parkinson’s, stroke, neuropathic pain, cancer, immunology, virology, and osteoporosis. Worked on different type of targets including proteases, GPCR, Ion channels, PPI, and Inflammasome etc. Addressed potency, selectivity, ADME, cardiovascular issues, toxicity etc. leading to identification of clinical candidates. Optimized synthetic routes suitable for bulk synthesis of API and outsourcing efforts for scale up. Strong knowledge in biophysics, pharmacology, biology, ADME and formulations. Inventor in 30 approved US patents and with additional 40 patent applications. Over ten years of experience in leading research projects, managed teams including chemistry, DMPK, pharmacology etc. Managed program that lead to a total sale of projects worth 500 million up front with over 2 billion in potential milestone. Additional duties involved setting up strategy, budget and timeline for projects and managing people in a matrix environment. Rich experience in managing external collaborations (Boehringer Ingelheim, Merck, etc.) CRO’s (Chemistry, DMPK, HTS screen etc.). Certified in Project Management and QA/RA for drug development. Key career highlights include clinical candidates for: SNDX-5613: Menin-MLL inhibitor of AML/ALL in phase 2a o IFM-2427 -NLRP3 Inhibitor BI01181181: Beta Secretase inhibitor for Alzheimer’s. o MK-2301 Human Immunodeficiency Virus (HIV) Integrase strand transfer inhibitor as back up for Isentress (Raltegravir) drug. o MK-0617; Very Late Antigen-4 (VLA4) antagonist for Multiple Sclerosis (MS). o L-006235; Cathepsin K inhibitor for Osteoporosis. •Specialties: Drug discovery, synthetic chemistry, analytical chemistry. target validation, application of biophysical methods to identify leads, PROTAC, SBDD, FBDD, etc.

Shankar Venkatraman

Proven drug discovery leader with over twenty years of drug discovery experience and successful trac...
Lansdale, Pennsylvania, United States

*50 free lookup(s) per month.

No credit card required.

Shankar Venkatraman’s Email svenkatraman@ifmthera.com

Shankar Venkatraman’s Phone Numbers

Get SHANKAR’s Phone Number (For Free)

Social Media

Shankar Venkatraman’s Location Lansdale, Pennsylvania, United States

Shankar Venkatraman’s Current Industry Ifm Therapeutics

Shankar Venkatraman’s Prior Industry Vitae Pharmaceuticals | Merck | Celeraaxys Pharmaceuticals | University Of Minnesota

Not the Shankar Venkatraman you were looking for?

Find accurate emails & phone numbers for over 700M professionals.

Work Experience

Ifm Therapeutics

Executive Director

2017-05-01 00:00:00 - Present

Vitae Pharmaceuticals

Director

2009-07-01 00:00:00 - 2017-04-01 00:00:00

Merck

Sr. Research Fellow

2001-01-01 00:00:00 - 2009-04-01 00:00:00

Celeraaxys Pharmaceuticals

Sr. Scientist

1996-10-01 00:00:00 - 2000-12-01 00:00:00

University Of Minnesota

graduate student

1987-01-01 00:00:00 - 1992-01-01 00:00:00

Skills

No Skills Available

Languages

No Languages Available

FAQ About Shankar Venkatraman

Shankar Venkatraman is located at
Lansdale, Pennsylvania, United States

Shankar Venkatraman is a Proven drug discovery leader with over twenty years of drug discovery experience and successful track record in managing programs with 8 IND filings and one drug (Revumenib). Managed programs starting from target validation to identification of hits via SBDD/FBDD/HTS/DEL/literature and utilized PROTAC’s, molecular glues, covalent inhibitors, and allosteric modulators a to identify development and clinical candidates. Extensive experience in peptide therapeutics (Enkephalin analogs, VLA4 antagonist, PCSK9). Broad experience in various disease pathology including Alzheimer’s, Parkinson’s, stroke, neuropathic pain, cancer, immunology, virology, and osteoporosis. Worked on different type of targets including proteases, GPCR, Ion channels, PPI, and Inflammasome etc. Addressed potency, selectivity, ADME, cardiovascular issues, toxicity etc. leading to identification of clinical candidates. Optimized synthetic routes suitable for bulk synthesis of API and outsourcing efforts for scale up. Strong knowledge in biophysics, pharmacology, biology, ADME and formulations. Inventor in 30 approved US patents and with additional 40 patent applications. Over ten years of experience in leading research projects, managed teams including chemistry, DMPK, pharmacology etc. Managed program that lead to a total sale of projects worth 500 million up front with over 2 billion in potential milestone. Additional duties involved setting up strategy, budget and timeline for projects and managing people in a matrix environment. Rich experience in managing external collaborations (Boehringer Ingelheim, Merck, etc.) CRO’s (Chemistry, DMPK, HTS screen etc.). Certified in Project Management and QA/RA for drug development. Key career highlights include clinical candidates for: SNDX-5613: Menin-MLL inhibitor of AML/ALL in phase 2a o IFM-2427 -NLRP3 Inhibitor BI01181181: Beta Secretase inhibitor for Alzheimer’s. o MK-2301 Human Immunodeficiency Virus (HIV) Integrase strand transfer inhibitor as back up for Isentress (Raltegravir) drug. o MK-0617; Very Late Antigen-4 (VLA4) antagonist for Multiple Sclerosis (MS). o L-006235; Cathepsin K inhibitor for Osteoporosis. •Specialties: Drug discovery, synthetic chemistry, analytical chemistry. target validation, application of biophysical methods to identify leads, PROTAC, SBDD, FBDD, etc.

Shankar Venkatraman currently works in the Ifm Therapeutics |

No Languages Available

Shankar Venkatraman has prior
experience in the following industries:
Vitae Pharmaceuticals | Merck | Celeraaxys Pharmaceuticals | University Of Minnesota

Shankar Venkatraman has the following professional experience:
Ifm Therapeutics | Vitae Pharmaceuticals | Merck | Celeraaxys Pharmaceuticals | University Of Minnesota